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Summary. Growth factors in general and transforming 
growth factor-a in particular have been related to cell 
proliferation and cell differentiation. This study was 
designed to clarify the distribution pattem of TGF-a in 
chemically-induced hepatocarcinogenesis. Sprague- 
Dawley rats were subjected to different non-intensive or 
intensive carcinogenic treatments using diethylni- 
trosamine (DEN) as carcinogen and ethinyl estradiol 
(EE) as promoter. The livers were fixed in 2% 
paraformaldehyde, dehydrated in a series of ethanol 
solutions, embedded in paraffin and sectioned. In the 
preneoplastic lesions no TGF-a immunoreactive cells 
were identified, but in some hepatic tumours cell 
immunostained with TGF-a antibody were observed. 
These results suggest that the cells capable of expressing 
TGF-a constitutively may be involved in neoplastic 
development in vivo. 
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lntroduction 
Transforming growth factor-a (TGF-a) was initially 
identified by its ability to induce proliferation of normal 
fibroblasts in a soft agar medium (De Larco and Todaro, 
1978). TGF-a is a 50-amino acid polypeptide derived 
from a 1 60-amino acid precursor (Massagué, 1990). 
The amino acid sequence of TGF-a has 35% identity 
with the epidermal growth factor (EGF) sequence, 
which includes the conservation of al1 six cysteine 
residues (Derynck et al., 1984). Two-dimensional NMR 
studies provide evidence than in solution the two 
proteins have very similar polypeptide chain folds and 
both EGF and TGF-a compete with each other for 
binding to the EGF-receptor (Winkler et al., 1989). 
Orrpn'nt requests to: Dr. Ricardo Pbrez-Tomás, Dept. de Biologla Celular 
y Anatomía Patolbgica, Facultad de Medicina, Avd. Diagonal 645 
(Pedralbes), Universidad de Barcelona, 08028 Barcelona, Spain 
TGF-a is expressed in placenta (Lee et al., 1985) and 
embryonic tissues (Brown et al., 1990) as well as in 
normal skin, the adult brain and the gastrointestinal tract 
(Coffey et al., 1987; Wilcox et al., 1988; Malden et al., 
1989). A number of human tumour cell lines, as well as 
biopsies from a range of human epithelium-derived 
tumours, have been found to co-express RNAs specific 
for TGF-a and EGF-R/c-erb B, renal cell carcinomas 
showing the highest levels of expression (Derynck et al., 
1987). Similar observations have also been reported for 
hepatocellular carcinomas and papillary carcinomas of 
the thyroid (Yeh et al., 1987; Aasland et al., 1990). 
Over- expression of TGF-a has been involved in 
psoriatic epidermal hyperplasia (Elder et al. 1989). The 
production of TGF-a by various tumour cells suggests 
that it may play an important role in cellular 
transformation when expressed abnormally (Sandgren et 
al., 1990). It has been proposed that TGF-a or other 
growth factors may play a role in tumour formation via 
an autocrine mechanism whereby TGFs help to sustain 
the transformed character of some of the cell populations 
from which they are secreted (Spom and Roberts, 1985). 
The aim of the present study is to determine the 
distribution of immunohistochemically demonstrable 
TGF-a expression in altered populations of hepatocytes 
during hepatocarcinogenesis. A pattern of TGF-a 
expression among a range of hepatic lesions from 
preneoplastic foci to hepatocellular carcinoma is 
presented and results are discussed with referente to the 
role of this growth factor in tumourogenesis. 
Materials and methods 
Animals and treatments 
Hepatic lesions were obtained from different 
carcinogenic protocols to Sprague-Dawley rats using 
Diethylnitrosamine (DEN) (Merck, Darmstadt, FRG) as 
carcinogen and Ethinyl estradiol (EE) (Sigma, St. 
Louis, Mo USA) as promoter. The animals were kept 
under altemate 12 - hours periods of light and darkness. 
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Graph 1. Non-intensive carcinogenic treatment. Protocols, NOO, NEO, 
NOE and NEE. DEN was administered as a single injection of 100 mg/Kg 
body weight. EE was incorporated into the diet at 10 p.p.m. and the 
periods of administration are shown by whie bars.. 
1 Multinodular carcinomas 1 4(7) 1 
1 Undifferentiated carcinomas 1 4(7) 1 
Well-dierentiated carcinomas 
1 
Neoplastic nodules 1 1(5) 1 
Table 1. Tumours from the intensive carcinogenic treatments which 
showed immunostaining to monoclonal antibody to TGF-a. In 
parenthesis, total number of tumours analyzed. 
smaller number were eosinophil and only a minority 
were basophil. No TGF-a irnmunoreactivity cells were 
observed in any of the these preneoplastic lesions. 
Macroscopic tumours, defined as those > 0.5 cm in 
diameter were counted in the livers of the animals 
under intensive carcinogen treatment. Bile duct 
hyperplasia and hypertrophy, small collangiomas and 
oval cells forming expansive trabeculae were found to a 
greater or lesser extent inside al1 the tumours of 
hepatocellular origin. Al1 the animals from the ICT-A 
protocol developed hepatic tumours. Histologically they 
were neoplastic nodules and well-differentiated 
carcinomas. In the intensive carcinogenic treatments 
from the ICT-B and ICT-C protocols al1 the animals also 
had tumours and, in addition to neoplastic nodules and 
well differentiated carcinomas, undifferentiated and 
multinodular carcinomas were identified. In al1 the 
tumour classes there were cases of TGF-a antibody 
immunoreactivity. Furthermore, it appeared that in the 
more advanced neoplastic lesions (multinodular and 
poorly differentiated carcinomas) TGF-a immunostaining 
was more frequent than in the less advanced ones 
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Graph 2. Intensive carcinogenic treatrnent. Protocols ICT-A, ICT-B and 
ICT-C. In the protocol ICT-A the dose of initiation with DEN was 230 
mg/Kg body weight Two weeks later a second dose of DEN (70 mgKg) 
was administered 24 hrs. after performing a partial hepatectomy (PH). In 
the protocols ICT-B and ICT-C the dose of initiation with DEN was 200 
mg/Kg body weight. In the protocol ICT-B the intensive doses of DEN 
were 40 mgKg body weight each week during 8 weeks (arrowheads). In 
the protowl ICT-C the intensive doses of DEN were 80 mg/kg body 
weight each week during 4 weeks (arrowheads). EE was incorporated 
into the diet at 10 p.p.m. and the periods of administration are shown by 
white bars. 
(neoplastic nodules) (Table 1). 
The cells immunoreactive to TGF-a antibody, 
displayed an atypical shape with a heterogeneous size 
(Figs. 1 - 3). Polynucleate (Figs. 3 - 5) or vacuolate 
(Figs. 3, 6) cells and occasionally, abnormal mitotic 
figures were seen. Numerous cystic and haemorrhagic 
lesions were also observed. Necrosis areas with 
degenerating or pyknotic cells were dispersed throughout 
the hepatic tumoral tissue. The neoplastic- 
immunoreactive-TGF-a cells were spread over large areas 
and also formed nodules or small groups of up to twenty 
cells (Fig. 6). None of the tumours was enterirely stained 
by the antibody; only subpopulations of them showed 
TGF-a immunoreactivity (Fig. 2). 
Discusslon 
Roden hepatocarcinogenesis is a multi-step process 
(Farber and Sarma, 1987), in which altered populations 
of hepatocytes arise dunng the carcinogenic treatments. 
Preneoplastic foci and nodules are thought to be the 
precursors of neoplastic tumour formation. High levels 
of the TGF-a mRNA in hepatocytes has been observed 
during liver regeneration, suggesting that a TGF-a 
autocrine circuit is transiently activated (Mead and 
Fausto, 1989). We were not able to detect 
immunohistochemically reactive TGF-a expression in 
TGF-a in rat hepatocarcinogenesis 
preneoplastic lesions of the liver. However, we found 
that TGF-a was detectable in some hepatic tumours. 
It appeared that the incidence of TGF-a positivie 
tumours was higher in carcinomas than in neoplastic 
benign nodules. No differences in this incidence 
were observed among the different types of carcinomas 
that we considered: well-differentiated homogeneous, 
well differentiated multinodular; and poorly differentiated 
hepatocellular carcinomas. These results suggest 
that TGF-.a expression in hepatic lesions during 
hepatocar-cinogenesis rnay be involved in the later steps 
of tumour formation, associated with the stage of 
progression. However, it does not seem to be an essential 
factor in the process of tumour formation, since 
there were hepatocellular carcinomas that did 
not show TGF-a immunoreactivity. Given the limited 
resolution of the immunohistochemical method used, it 
cannot be ruled out that low levels of TGF-a expression 
in those immunohistochemically-negative turnours 
could also be involved in their neoplastic development 
process. In some of the animals with hepatocellular 
carcinomas, pulmonary micrometastasis from the liver 
arose (data not shown) and immunohistochemistry for 
TGF-a showed that they were al1 negative for the 
factor. Furthermore, there was no preferential staining in 
the more advanced tumours such as multinodular 
or poorly differentiated ones. Therefore, although 
TGF-a rnay play a role in liver tumour progression, 
presumably by binding to and activating EGF-receptors, 
which are abundant in the rodent liver (Gladhaug 
and Christoffersen, 1988), it does not seem to be 
involved in the processes leading to the acquisition of 
malignancy. 
Previous studies have also indicated that TGF-a is a 
potent inducer of angiogenesis in a model in vivo 
(Schreiber et al., 1986). Haematopoietic tumours 
which do not require neovascularization for their 
development do not contain TGF-a mRNA. However, 
the endogenous synthesis of TGF-a in various types 
of solid tumours rnay not only contribute to an autocrine 
growth stimulation of these tumour cells, but 
rnay also play a paracrine role in the tumour-induced 
angiogenesis, probably in conjunction with 
other angiogenic factors similar to TGF-B (Evarts et al., 
1990). Massive proliferation of endothelial cell 
was not characteristic in our tumours, thus further 
study is required to elucidate the involvement of 
TGF-a as an angiogenic growth factor in hepato- 
carcinogenesis. 
Jhappan et al. (1990) affirm that TGF-a specific 
lesions rnay arise predominantly in tissues containing 
cells that are highly responsive to TGF-a/EGF, owing to 
the possession of either excessive endogenous EGF- 
receptors, as in the liver, or a more productive signal 
transduction pathway. Thus, in our rats, liver 
carcinogenesis may involve, at least in part, the selection 
of cells capable of expressing constitutive TGF-a, which 
rnay be of significance for the development of 
malignancies in vivo. 
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